2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesis

Hirotoshi Iihara; Masakazu Abe; Makoto Wada; Keiko Iino; Tatsuo Akechi; Chiyo K Imamura; Ayako Okuyama; Keiko Ozawa; Yong-Il Kim; Hidenori Sasaki; Eriko Satomi; Masayuki Takeda; Ryuhei Tanaka; Takako Eguchi Nakajima; Naoki Nakamura; Junichi Nishimura; Mayumi Noda; Kazumi Hayashi; Takahiro Higashi; Narikazu Boku; Koji Matsumoto; Yoko Matsumoto; Kenji Okita; Nobuyuki Yamamoto; Kenjiro Aogi

doi:10.1007/s10147-024-02535-x

2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesis

Int J Clin Oncol. 2024 May 16. doi: 10.1007/s10147-024-02535-x. Online ahead of print.

Authors

Hirotoshi Iihara¹, Masakazu Abe², Makoto Wada³, Keiko Iino⁴, Tatsuo Akechi⁵, Chiyo K Imamura⁶, Ayako Okuyama⁷, Keiko Ozawa⁸, Yong-Il Kim⁹, Hidenori Sasaki¹⁰, Eriko Satomi¹¹, Masayuki Takeda¹², Ryuhei Tanaka¹³, Takako Eguchi Nakajima¹⁴, Naoki Nakamura¹⁵, Junichi Nishimura¹⁶, Mayumi Noda¹⁷, Kazumi Hayashi¹⁸, Takahiro Higashi¹⁹, Narikazu Boku²⁰, Koji Matsumoto²¹, Yoko Matsumoto²², Kenji Okita²³, Nobuyuki Yamamoto²⁴, Kenjiro Aogi²⁵

Affiliations

¹ Department of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, 501-1194, Japan.
² Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-Ku, Hamamatsu, Shizuoka, 431-3192, Japan.
³ Department of Psycho‑Oncology and Palliative Medicine, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-Ku, Osaka, Osaka, 541-8567, Japan.
⁴ School of Nursing, National College of Nursing, Japan, 1-2-1, Umezono, Kiyose, Tokyo, 204-8575, Japan.
⁵ Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-Cho, Mizuho-Ku, Nagoya, 467-8601, Japan.
⁶ Advanced Cancer Translational Research Institute, Showa University, 1-5-8 Hatanodai, Shinagawa-Ku, Tokyo, 142-8555, Japan.
⁷ Graduate School of Nursing Science, St. Luke's International University, 10-1 Akashi-Cho, Chuo-Ku, Tokyo, 104-0044, Japan.
⁸ Division of Survivorship, Institute for Cancer Control, National Cancer Center, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
⁹ Division of Medical Oncology, Yodogawa Christian Hospital, 1-7-50 Kunijima, Higasiyodogawa-Ku, Osaka, Osaka, 533-0024, Japan.
¹⁰ Division of Medical Oncology, Hematology and Infectious Disease, Fukuoka University Hospital, 7-45-1, Nanakuma, Jonan-Ku, Fukuoka, 814-0180, Japan.
¹¹ Department of Palliative Medicine, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
¹² Department of Cancer Genomics and Medical Oncology, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8521, Japan.
¹³ Department of Pediatric Hematology/Oncology, International Medical Center, Saitama Medical University, 1398-1 Yamane, Hidaka, Saitama, 350-1298, Japan.
¹⁴ Department of Early Clinical Development, Kyoto University Graduate School of Medicine, 54 Kawahara-Cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
¹⁵ Department of Radiation Oncology, St. Marianna University, 2-16-1, Sugao, Miyamae, Kawasaki, Kanagawa, 216-8511, Japan.
¹⁶ Department of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-Ku, Osaka, 541-8567, Japan.
¹⁷ Non-Profit Organizaition Sasaeau-Kai "Alpha", 518-7 Kawado-Cho, Chuo-Ku, Chiba, 260-0802, Japan.
¹⁸ Department of Clinical Oncology and Hematology, The Jikei University School of Medicine, 3-25-8 Nishi-Shinnbashi Minatoku, Tokyo, 105-8461, Japan.
¹⁹ Department of Public Health and Health Policy, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-0033, Japan.
²⁰ Department of Oncology and General Medicine, IMSUT Hospital, Institute of Medical Science, University of Tokyo, 4-6-1 Shiroganedai, Minato-Ku, Tokyo, 108-8639, Japan.
²¹ Division of Medical Oncology, Hyogo Cancer Center, 13-70 Kitaoji-Cho, Akashi, Hyogo, 673-0021, Japan.
²² Non-Profit Organization Ehime Cancer Support "Orange-No-Kai", 3-8-24 Furukawaminami, Matsuyama, Ehime, 790-0943, Japan.
²³ Department of Surgery, Otaru Ekisaikai Hospital, 1-4-1, Inaho, Otaru, Hokkaido, 047-0032, Japan.
²⁴ Internal Medicine III, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan.
²⁵ Department of Breast Surgery, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minamiumemoto-Machi, Matsuyama, Ehime, 791-0280, Japan. aogi.kenjiro.zx@mail.hosp.go.jp.

PMID: 38753042
DOI: 10.1007/s10147-024-02535-x

Abstract

Background: The Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis 2023 was extensively revised to reflect the latest advances in antineoplastic agents, antiemetics, and antineoplastic regimens. This update provides new evidence on the efficacy of antiemetic regimens.

Methods: Guided by the Minds Clinical Practice Guideline Development Manual of 2017, a rigorous approach was used to update the guidelines; a thorough literature search was conducted from January 1, 1990, to December 31, 2020.

Results: Comprehensive process resulted in the creation of 13 background questions (BQs), 12 clinical questions (CQs), and three future research questions (FQs). Moreover, the emetic risk classification was also updated.

Conclusions: The primary goal of the present guidelines is to provide comprehensive information and facilitate informed decision-making, regarding antiemetic therapy, for both patients and healthcare providers.

Keywords: Antiemesis; CINV; Cancer chemotherapy; Clinical practice guidelines; Nausea; Vomiting.